Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report
/in Gallbladder Cancer, Hyperthermia, International Publications /von 2017-07-26 / Integr Cancer Ther 2018 06;17(2):558-561Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2013-07-20 / J. Gastrointest. Surg. 2013 Sep;17(9):1609-17Current status of immunotherapy for the treatment of biliary tract cancer
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-72A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors
/in Dendritic Cells, Gallbladder Cancer, International Publications, Pancreatic Cancer /von 2008-01-01 / Cancer Ther 2008;6(B):955-964Successful immunological treatment of gallbladder cancer in India–case report
/in Gallbladder Cancer, International Publications /von 2006-09-01 / J Zhejiang Univ Sci B 2006 Sep;7(9):719-24Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case
/in Gallbladder Cancer, International Publications /von 2006-01-01 / Surg. Today 2006;36(6):559-62Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma
/in Gallbladder Cancer, International Publications /von 2005-08-01 / Oncol. Rep. 2005 Aug;14(2):353-6Effects of dendritic cells transfected with full length wild-type p53 and modified by bile duct cancer lysates on immune response
/in Gallbladder Cancer, International Publications /von 2005-02-01 / HBPD INT 2005 Feb;4(1):121-5Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma
/in Gallbladder Cancer, International Publications /von 2004-07-01 / Hum. Pathol. 2004 Jul;35(7):881-6IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de